Most investors are probably aware that the healthcare industry slowed significantly during the recession and has been very slow in coming back. Hospitals have pulled back on capital spending and procedure counts have dropped as would-be patients worry about inadequate insurance coverage, higher co-pays and/or the opportunity to take time off for recuperation.

There's another segment of the healthcare industry, though; one built around elective procedures that is generally not covered by health insurance. Aesthetics is a big part of this segment, and the market for skin tightening, rejuvenation and so on nearly collapsed in the recession. Procedure counts are starting to come back, though, and Solta Medical (Nasdaq:SLTM) is a risky name worth checking out by virtue of its differentiated business model and new LipoSonix body-sculpting line.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers

The Opportunity to Fatten up from LipoSonix
One of the biggest changes to Solta in recent times has come from the acquisition and launch of the LipoSonix body-sculpting system. LipoSonix was developed for a time by large dermatology and aesthetics company Medicis (NYSE:MRX), but the company made modest progress and ultimately decided that it was outside of the core focus. Solta stepped up and acquired the platform for $35 million in cash and various earn-outs that will stretch over a number of years.

LipoSonix uses high intensity focused ultrasound (HIFU) to destroy fat cells. It's not medically equivalent to liposuction, but it is a safe and is a relatively comfortable way of reducing fat deposits under the skin and can be used for so-called "body sculpting" procedures.

Solta is neither alone nor first to market; Zeltiq (Nasdaq:ZLTQ) has been marketing its CoolSculpting product for a little while now, while companies like Syneron (Nasdaq:ELOS) and Palomar (Nasdaq:PMTI) market laser-based body sculpting products. Nevertheless, Solta's newest LipoSonix is off to a good start; a worldwide launch in the first quarter of 2012 saw better-than-expected demand and nearly 80 system installations.

SEE: 5 Financial Moves That Can Make You Fat

Will a Differentiated Model Pay off?
In the aesthetics industry, the historical norm has been to build and sell relatively expensive systems with reusable (and expensive) hand pieces. This requires the doctor to make a relatively large upfront capital commitment and then earn that back with per-procedure costs.

Solta has tried a different approach. While Solta's systems are not cheap, the company's Thermage, Fraxel and Isolaz platforms feature much cheaper disposable tips. This reduces the upfront cost for the doctor, and allows Solta to book a lucrative ongoing stream of high-margin revenue that is directly correlated to system usage. The company still has to deal with the fact that rivals like Syneron and Cynosure (Nasdaq:CYNO) have larger share (and Palomar reaps substantial licensing revenue for its technology), but there is a fair bit of turnover in this market and the useful life of the systems is around five to 10 years.

Solta has also tried to build its brand by marketing directly to potential aesthetics procedure customers. While there's some legitimacy to the idea that an "ask for it by name" campaign could lead practitioners to buy Solta systems if enough customers ask about it, the reality is that this is very much a market that is driven by word of mouth and direct recommendations. In other words, patrons of aesthetic procedures are more likely to recommend the doc and the procedure and by relatively little notice to the name on the hand piece.

SEE: Which Is Better: Dominance Or Innovation

The Bottom Line
The aesthetic procedure market is definitely still well below its heyday, but the market isn't as bad as the stock valuations suggest. There has been a recovery in procedure counts, and the market seems to be getting slowly better. What's more, Solta has the advantage of fresh LipoSonix revenue to drive better growth.

At less than 1.5 times trailing revenue, Solta is not getting much regard by the market, and that could spell opportunity for aggressive risk-tolerant investors. I'd like to see a quarter or two of margin outperformance (as well as stronger disposables sales) before really buying in, but a strong launch of LipoSonix and a larger aesthetics market recovery could fuel strong gains here in time.

At the time of writing, Stephen Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  2. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  3. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  4. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  5. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  6. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  7. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  8. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  9. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  10. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center